

# Piotr Ponikowski

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4019717/publications.pdf](https://exaly.com/author-pdf/4019717/publications.pdf)

Version: 2024-02-01

746  
papers

198,462  
citations

179

149  
h-index

24

427  
g-index

796  
all docs

796  
docs citations

796  
times ranked

119416  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction. <i>Cardiology Journal</i> , 2024, 31, 300-308.	1.3	0
2	Global Rounds: Poland. <i>Circulation</i> , 2024, 149, 174-176.	9.3	0
3	Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial. <i>Circulation: Heart Failure</i> , 2024, 17, .	4.2	0
4	Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial. <i>Circulation: Heart Failure</i> , 2024, 17, .	4.2	4
5	Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. <i>Circulation</i> , 2024, 149, 1627-1638.	9.3	8
6	Redefining Iron Deficiency in Patients With Chronic Heart Failure. <i>Circulation</i> , 2024, 150, 151-161.	9.3	2
7	Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. <i>European Heart Journal</i> , 2023, 44, 41-50.	2.3	95
8	Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. <i>Circulation</i> , 2023, 147, 624-634.	9.3	30
9	Inflammatory activation biomarker profile after marathon running and its impact on cardiovascular stress in amateur middle-aged male runners. <i>Advances in Clinical and Experimental Medicine</i> , 2023, 32, 0-0.	1.6	2
10	Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.9	2
11	Impact of mitral regurgitation in patients with acute heart failure: insights from the <sc>RELAX&Aacute;AHF</sc> trial. <i>European Journal of Heart Failure</i> , 2023, 25, 541-552.	7.5	5
12	Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF. <i>Circulation</i> , 2023, 147, 1670-1683.	9.3	13
13	The win ratio method in heart failure trials: lessons learnt from <sc>EMPULSE</sc>. <i>European Journal of Heart Failure</i> , 2023, 25, 632-641.	7.5	12
14	Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis. <i>Circulation</i> , 2023, 147, 1640-1653.	9.3	14
15	Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial. <i>Circulation: Heart Failure</i> , 2023, 16, .	4.2	6
16	Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat. <i>Circulation: Heart Failure</i> , 2023, 16, .	4.2	0
17	Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. <i>European Heart Journal</i> , 2023, 44, 5077-5091.	2.3	44
18	Acute Heart Failure Is a Malignant Process: But We Can Induce Remission. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.9	5

#	ARTICLE	IF	CITATIONS
19	Iron Deficiency in Heart Failure: A Korea-Oriented Review. International Journal of Heart Failure, 2023, 5, 173.	0.0	0
20	Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circulation: Heart Failure, 2023, 16, .	4.2	0
21	Effects of an outpatient intervention comprising nurse-led non-invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (<sc>AMULET</sc> study): a randomised controlled trial. European Journal of Heart Failure, 2022, 24, 565-577.	7.5	29
22	Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design. Advances in Medical Sciences, 2022, 67, 18-22.	2.2	7
23	Valsalva-derived Measures and Phenylephrine Test in Patients With Heart Failure With Reduced Ejection Fraction Receiving Comprehensive Neurohormonal Blockade Drug Therapy: A 5-year Event-free Survival Analysis. Journal of Cardiac Failure, 2022, 28, 744-755.	1.7	1
24	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology, the, 2022, 10, 24-34.	11.3	42
25	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <sc>DAPA-HF</sc>. European Journal of Heart Failure, 2022, 24, 513-525.	7.5	41
26	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation, 2022, 145, 184-193.	9.3	123
27	Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. JACC: Heart Failure, 2022, 10, 52-64.	5.2	13
28	Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the <sc>BIOSTAT-HF</sc> study. European Journal of Heart Failure, 2022, 24, 192-204.	7.5	24
29	Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. European Journal of Heart Failure, 2022, 24, 308-320.	7.5	12
30	Performance Comparison of Au-Based and Au-Free AlGaIn/GaN HEMT on Silicon. IEEE Transactions on Electron Devices, 2022, 69, 1014-1019.	3.2	7
31	Hemosiderin Accumulation in Liver Decreases Iron Availability in Tachycardia-Induced Porcine Congestive Heart Failure Model. International Journal of Molecular Sciences, 2022, 23, 1026.	4.2	6
32	Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 431-441.	7.5	80
33	Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in <sc>DAPA-HF</sc>. European Journal of Heart Failure, 2022, 24, 1066-1076.	7.5	33
34	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.5	1,057
35	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF. JACC: Heart Failure, 2022, 10, 104-118.	5.2	5
36	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 228-239.	4.4	7

#	ARTICLE	IF	CITATIONS
37	Early Hemodynamic Changes following Surgical Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction. <i>Journal of Clinical Medicine</i> , 2022, 11, 1063.	2.5	2
38	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. <i>Nature Medicine</i> , 2022, 28, 568-574.	30.1	430
39	Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>JACC Asia</i> , 2022, 2, 139-153.	2.2	3
40	Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, 24, 821-832.	7.5	17
41	Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 782-790.	7.5	19
42	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. <i>Clinical Research in Cardiology</i> , 2022, 111, 912-923.	3.5	12
43	Responder analysis for improvement in 6-minute walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, 24, 833-842.	7.5	9
44	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008970.	4.2	11
45	Relationship of Dapagliflozin With Serum Sodium. <i>JACC: Heart Failure</i> , 2022, 10, 306-318.	5.2	10
46	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. <i>Circulation</i> , 2022, 146, 279-288.	9.3	81
47	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2022, 43, 863-867.	2.3	19
48	Contribution of Peripheral Chemoreceptors to Exercise Intolerance in Heart Failure. <i>Frontiers in Physiology</i> , 2022, 13, 878363.	2.8	2
49	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. <i>Circulation</i> , 2022, 146, 438-449.	9.3	72
50	Clinical implications of low estimated protein intake in patients with heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1762-1770.	7.4	12
51	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. <i>Annals of Internal Medicine</i> , 2022, 175, 820-830.	10.2	68
52	Biomarkers of Myocardial Injury and Remodeling in Heart Failure. <i>Journal of Personalized Medicine</i> , 2022, 12, 799.	2.6	18
53	Novel Biomarkers of Renal Dysfunction and Congestion in Heart Failure. <i>Journal of Personalized Medicine</i> , 2022, 12, 898.	2.6	2
54	Induction of Day-Time Periodic Breathing is Associated With Augmented Reflex Response From Peripheral Chemoreceptors in Male Patients With Systolic Heart Failure. <i>Frontiers in Physiology</i> , 2022, 13, .	2.8	0

#	ARTICLE	IF	CITATIONS
55	Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	4.2	14
56	Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF. <i>JACC: Heart Failure</i> , 2022, 10, 651-661.	5.2	12
57	Novel Phenotyping for Acute Heart Failure—Unsupervised Machine Learning-Based Approach. <i>Biomedicines</i> , 2022, 10, 1514.	3.3	8
58	Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1614-1622.	7.5	19
59	Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1-18.	5.6	30
60	Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. <i>Circulation</i> , 2022, 146, 980-994.	9.3	72
61	Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2022, 146, 1046-1055.	9.3	32
62	Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients. <i>European Journal of Heart Failure</i> , 2021, 23, 729-739.	7.5	38
63	High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. <i>European Journal of Heart Failure</i> , 2021, 23, 919-932.	7.5	54
64	Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. <i>American Journal of Medicine</i> , 2021, 134, 482-489.	1.4	56
65	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 298-309.	9.3	211
66	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 117-128.	30.1	1,212
67	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	30.1	413
68	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. <i>Circulation</i> , 2021, 143, 337-349.	9.3	240
69	Effects of a Novel Nitroxyl Donor in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 146-157.	5.2	20
70	Is acute heart failure a distinctive disorder? An analysis from <i>BIOSTAT-CHF</i> . <i>European Journal of Heart Failure</i> , 2021, 23, 43-57.	7.5	20
71	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the <i>RELAX-AHF</i> study. <i>European Journal of Heart Failure</i> , 2021, 23, 58-67.	7.5	10
72	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 1203-1212.	2.3	126

#	ARTICLE	IF	CITATIONS
73	Prediction of AF in Heart Failure With Preserved Ejection Fraction. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 131-144.	6.0	33
74	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of <sc>DAPA-HF</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 632-643.	7.5	25
75	Antiplatelets in acute coronary syndrome in Poland – from guidelines to clinical practice. <i>Postępy W Kardiologii Interwencyjnej</i> , 2021, 17, 141-154.	0.2	2
76	Nurse-led ambulatory care supported by non-invasive haemodynamic assessment after acute heart failure decompensation. <i>ESC Heart Failure</i> , 2021, 8, 1018-1026.	3.1	8
77	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. <i>ESC Heart Failure</i> , 2021, 8, 861-871.	3.1	21
78	Comparison of left ventricular longitudinal systolic function parameters in the prediction of adverse outcome in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 1531-1540.	3.1	10
79	Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction. <i>Kardiologia Polska</i> , 2021, 79, 363-370.	0.6	4
80	Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the <sc>EMPULSE</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 826-834.	7.5	69
81	Effect of dapagliflozin on anaemia in <sc>DAPA-HF</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 617-628.	7.5	64
82	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021, 23, 527-540.	7.5	45
83	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. <i>European Heart Journal</i> , 2021, 42, 1254-1269.	2.3	87
84	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the <sc>DAPA-HF</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 601-613.	7.5	35
85	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. <i>European Journal of Heart Failure</i> , 2021, 23, 352-380.	7.5	749
86	Oxygenation pattern and compensatory responses to hypoxia and hypercapnia following bilateral carotid body resection in humans. <i>Journal of Physiology</i> , 2021, 599, 2323-2340.	2.9	17
87	Rationale and design of the AMULET study: A new Model of telemedical care in patients with heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2569-2579.	3.1	16
88	Not all fluid overloads are the same: some practical considerations for better decongestion. <i>European Journal of Heart Failure</i> , 2021, 23, 1106-1109.	7.5	5
89	Transvenous Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea: Five-Year Safety and Efficacy Outcomes. <i>Nature and Science of Sleep</i> , 2021, Volume 13, 515-526.	2.8	33
90	Primary Human Cardiomyocytes and Cardiofibroblasts Treated with Sera from Myocarditis Patients Exhibit an Increased Iron Demand and Complex Changes in the Gene Expression. <i>Cells</i> , 2021, 10, 818.	4.3	8

#	ARTICLE	IF	CITATIONS
91	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 387-413.	1.7	435
92	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. <i>JACC: Heart Failure</i> , 2021, 9, 254-264.	5.2	81
93	Iron status, catabolic/anabolic balance, and skeletal muscle performance in men with heart failure with reduced ejection fraction. <i>Cardiology Journal</i> , 2021, 28, 391-401.	1.3	5
94	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <sc>Heart Failure Association of the European Society of Cardiology</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 872-881.	7.5	180
95	FC 021 EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY FOLLOWING ACUTE HEART FAILURE, ACCORDING TO BASELINE EGFR: A SUBGROUP ANALYSIS OF THE AFFIRM-AHF TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.8	1
96	Targeting Iron Deficiency in Heart Failure: Existing Evidence and Future Expectations. <i>Circulation: Heart Failure</i> , 2021, 14, e008299.	4.2	7
97	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021, 143, 1962-1972.	9.3	39
98	Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge. <i>ESC Heart Failure</i> , 2021, 8, 2597-2602.	3.1	21
99	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 499.	6.5	135
100	Low ventilatory responsiveness to transient hypoxia or breath-holding predicts fast marathon performance in healthy middle-aged and older men. <i>Scientific Reports</i> , 2021, 11, 10255.	3.4	1
101	Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising <sc>AFFIRM-AHF</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 1687-1697.	7.5	24
102	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the <sc>VICTORIA</sc> (<sc>Vericiguat</sc> Global Study in Tj ETQq0 0 0 rg 85/Overlook 10 Tf 50	7.5	68
103	Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 678.	6.5	30
104	Catabolic/Anabolic Imbalance Is Accompanied by Changes of Left Ventricular Steroid Nuclear Receptor Expression in Tachycardia-Induced Systolic Heart Failure in Male Pigs. <i>Journal of Cardiac Failure</i> , 2021, 27, 682-692.	1.7	3
105	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1298.	6.5	12
106	Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. <i>Journal of the American College of Cardiology</i> , 2021, 78, 97-108.	5.6	78
107	Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the <sc>VICTORIA</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1300-1312.	7.5	40
108	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 808-811.	1.7	8

#	ARTICLE	IF	CITATIONS
109	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. <i>European Journal of Heart Failure</i> , 2021, 23, 1662-1672.	7.5	41
110	Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. <i>European Journal of Heart Failure</i> , 2021, 23, 1677-1686.	7.5	12
111	Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. <i>Circulation</i> , 2021, 144, 1265-1267.	9.3	5
112	Pol-tako – the first, nationwide Polish multicenter analysis of patients with takotsubo syndrome. <i>Kardiologia Polska</i> , 2021, 79, 867-869.	0.6	1
113	The short-term benefit from nurse-led ambulatory care supported by non-invasive haemodynamic assessment in patients after acute heart failure decompensation depends on time since hospital discharge. <i>Kardiologia Polska</i> , 2021, 79, 855-857.	0.6	0
114	Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , 2021, 23, 1597-1609.	7.5	26
115	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	10.2	40
116	Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2021, 23, 1750-1758.	7.5	35
117	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). <i>Circulation</i> , 2021, 144, 1489-1499.	9.3	26
118	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , 2021, 42, 3727-3738.	2.3	137
119	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	30.1	2,520
120	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	2.3	6,641
121	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. <i>ESC Heart Failure</i> , 2021, 8, 4409-4424.	3.1	9
122	Intravenous ferric carboxymaltose does not provide benefits in reperfused acute myocardial infarction in the rat with normal iron status. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111893.	5.8	4
123	Role of skeletal muscle perfusion and insulin resistance in the effect of dietary sodium on heart function in overweight. <i>ESC Heart Failure</i> , 2021, 8, 5304-5315.	3.1	4
124	Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry. <i>ESC Heart Failure</i> , 2021, 8, 4955-4967.	3.1	29
125	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1337-1348.	5.6	59
126	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. <i>ESC Heart Failure</i> , 2021, 8, 4394-4408.	3.1	7



#	ARTICLE	IF	CITATIONS
127	Intravenous iron supplementation: novel anti-remodelling therapy for patients with heart failure?. European Heart Journal, 2021, , .	2.3	6
128	Clinical Outcome Predictions for the VerlCiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. Journal of Cardiac Failure, 2021, 27, 949-956.	1.7	8
129	Amended <sc>STRONG&#x2013; study design. European Journal of Heart Failure, 2021, 23, 1981-1982.	7.5	12
130	HFA of the ESC position paper on the management of LVAD&#x2013;supported patients for the non&#x2013;LVAD specialist healthcare provider Part 3: at the hospital and discharge. ESC Heart Failure, 2021, 8, 4425-4443.	3.1	12
131	Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure. European Heart Journal, 2021, 42, 4468-4477.	2.3	18
132	Pathophysiology of Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 519-531.	2.4	10
133	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. European Heart Journal, 2021, 42, 700-710.	2.3	130
134	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. European Heart Journal, 2021, 42, 3011-3020.	2.3	77
135	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care, 2021, 44, 586-594.	9.1	52
136	<sc>COVID</sc>&#x2013;19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1806-1818.	7.5	38
137	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart&#x2013;Failure. JACC: Heart Failure, 2021, 9, 890-903.	5.2	8
138	Acute hyperoxia reveals tonic influence of peripheral chemoreceptors on systemic vascular resistance in heart failure patients. Scientific Reports, 2021, 11, 20823.	3.4	8
139	Distinct renin/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure. International Journal of Cardiology, 2021, 345, 54-60.	1.6	17
140	Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure. Biomolecules, 2021, 11, 1701.	4.2	7
141	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Circulation: Heart Failure, 2021, 14, CIRC&#x2013;HEART&#x2013;FAILURE121008837.	4.2	22
142	Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline&#x2013;directed medical therapy in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 1999-2007.	7.5	27
143	128&#x2013;Clinical impact of changes in mitral regurgitation severity after optimization of medical therapy in heart failure: insights from BIOSTAT-CHF. European Heart Journal Supplements, 2021, 23, .	0.1	0
144	Iron deficiency as an emerging therapeutic target in patients stabilized after an episode of acute heart failure. Cardiology Journal, 2021, 28, 962-969.	1.3	2

#	ARTICLE	IF	CITATIONS
145	Expression of sex steroid receptors and aromatase in adipose tissue in different body regions in men with coronary artery disease with and without ischemic systolic heart failure. <i>Aging Male</i> , 2020, 23, 141-153.	2.0	10
146	Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. <i>European Journal of Heart Failure</i> , 2020, 22, 70-80.	7.5	31
147	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 1147-1155.	7.5	55
148	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 519-527.	7.5	16
149	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 315-329.	7.5	25
150	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. <i>Circulation</i> , 2020, 141, 100-111.	9.3	152
151	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 141, 90-99.	9.3	259
152	Clinical value of pre-discharge bioadrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. <i>European Journal of Heart Failure</i> , 2020, 22, 683-691.	7.5	37
153	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 196-213.	7.5	137
154	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 931-939.	5.2	95
155	Heart Failure Association of the European Society of Cardiology update on sodium-glucose cotransporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	7.5	66
156	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	7.5	49
157	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1512.	7.0	194
158	Myocardial iron content in non-ischaemic cardiomyopathy: how much is known?. <i>European Journal of Heart Failure</i> , 2020, 22, 2047-2048.	7.5	3
159	Cause of Death in Patients With Acute Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 999-1008.	5.2	12
160	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , 2020, 396, 1895-1904.	12.1	462
161	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2383-2392.	7.5	97
162	Elevated plasma endothelin-1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 3536-3544.	3.1	15

#	ARTICLE	IF	CITATIONS
163	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 2272-2289.	7.5	113
164	Corrigendum to "Trimetazidine in cardiovascular medicine," [Int. J. Cardiol., 293 (2019) 39-44]. International Journal of Cardiology, 2020, 320, 26.	1.6	1
165	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 142, 1623-1632.	9.3	57
166	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. European Heart Journal, 2020, 41, 3787-3797.	2.3	116
167	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 2020, 383, 1413-1424.	30.1	3,134
168	Distinct clinical phenotypes of congestion in acute heart failure: characteristics, treatment response, and outcomes. ESC Heart Failure, 2020, 7, 3830-3840.	3.1	10
169	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 2020, 41, 3402-3418.	2.3	97
170	Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure. Circulation: Heart Failure, 2020, 13, e007879.	4.2	14
171	10-Year trends in hospitalization rates due to heart failure and related in-hospital mortality in Poland (2010-2019). ESC Heart Failure, 2020, 7, 3365-3373.	3.1	7
172	The Effects of a Marathon Effort on Psychomotor Performance and Catecholamine Concentration in Runners over 50 Years of Age. Applied Sciences (Switzerland), 2020, 10, 2067.	2.6	8
173	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. European Heart Journal, 2020, 41, 1810-1817.	2.3	391
174	Management of heart failure patients with <scp>COVID</scp>-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 941-956.	7.5	99
175	Looking at the heart failure through the prism of liver dysfunction. European Journal of Heart Failure, 2020, 22, 1672-1674.	7.5	5
176	Efficacy and safety of sodium-glucose cotransporter <scp>2</scp> inhibition according to left ventricular ejection fraction in <scp>DAPA-HF</scp>. European Journal of Heart Failure, 2020, 22, 1247-1258.	7.5	30
177	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117.	2.3	68
178	Re: Pacing, takotsubo syndrome, and transient rise of pacing threshold: What is the mechanism?. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 772-773.	1.2	0
179	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1353.	7.0	362
180	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2020, 382, 1883-1893.	30.1	844

#	ARTICLE	IF	CITATIONS
181	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , 2020, 41, 2379-2392.	2.3	156
182	How to diagnose heart failure with preserved ejection fraction: the HFAâ€PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 391-412.	7.5	213
183	Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAXâ€AHFâ€2 trial. <i>European Journal of Heart Failure</i> , 2020, 22, 726-738.	7.5	24
184	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan. <i>JACC: Heart Failure</i> , 2020, 8, 811-818.	5.2	93
185	Sodiumâ€glucose coâ€transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1495-1503.	7.5	103
186	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. <i>Clinical Research in Cardiology</i> , 2020, 109, 967-977.	3.5	7
187	Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 999-1005.	7.5	78
188	Megaâ€trials in heart failure: effects of dilution in examination of new therapies. <i>European Journal of Heart Failure</i> , 2020, 22, 1698-1707.	7.5	11
189	Frailty and cognitive impairment are predictive of takotsubo syndrome following pacemaker implantation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 730-736.	1.2	2
190	Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2020, 109, 1048-1059.	3.5	22
191	Cardiac emergencies during the coronavirus disease 2019 pandemic in the light of the current evidence. <i>Kardiologia Polska</i> , 2020, 78, 818-824.	0.6	7
192	On the search for the right definition of heart failure with preserved ejection fraction. <i>Cardiology Journal</i> , 2020, 27, 449-468.	1.3	14
193	Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns. <i>Kardiologia Polska</i> , 2020, 78, 811-817.	0.6	2
194	Medical emergency team interventions in patients with ST-segment elevation myocardial infarction in Poland in 2018. <i>Kardiologia Polska</i> , 2020, 78, 292-299.	0.6	3
195	Effects of running a marathon on irisin concentration in men aged over 50. <i>Journal of Physiological Sciences</i> , 2019, 69, 79-84.	2.2	7
196	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	2.3	4,856
197	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90.	1.4	420
198	Safety, Tolerability and efficacy of Rapid Optimization, helped by NTâ€proBNP and GDFâ€15, of Heart Failure therapies (STRONGâ€HF): rationale and design for a multicentre, randomized, parallelâ€group study. <i>European Journal of Heart Failure</i> , 2019, 21, 1459-1467.	7.5	40

#	ARTICLE	IF	CITATIONS
199	Effects of Serelaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , 2019, 381, 716-726.	30.1	195
200	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	7.5	162
201	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 866-874.	1.7	17
202	The Dapagliflozin And Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. <i>European Journal of Heart Failure</i> , 2019, 21, 1402-1411.	7.5	168
203	Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. <i>ESC Heart Failure</i> , 2019, 6, 1188-1198.	3.1	23
204	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1561-1570.	7.5	10
205	Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1299-1305.	7.5	163
206	Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. <i>JACC: Heart Failure</i> , 2019, 7, 970-979.	5.2	28
207	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2019, 40, 3297-3317.	2.3	1,075
208	Association between Left Ventricular Ejection Fraction and Worsening Renal Function in Acute Heart Failure: Insights from the RELAX-AHF-2 Trial. <i>Journal of Cardiac Failure</i> , 2019, 25, S51.	1.7	0
209	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1995-2008.	30.1	4,502
210	Long-term efficacy and safety of phrenic nerve stimulation for the treatment of central sleep apnea. <i>Sleep</i> , 2019, 42, .	1.1	40
211	Hypoxic tachycardia is not a result of increased respiratory activity in healthy subjects. <i>Experimental Physiology</i> , 2019, 104, 476-489.	2.0	11
212	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 1169-1186.	7.5	506
213	Controlled decongestion by Reprieve therapy in acute heart failure: results of the TARGET-1 and TARGET-2 studies. <i>European Journal of Heart Failure</i> , 2019, 21, 1079-1087.	7.5	29
214	Trimetazidine in cardiovascular medicine. <i>International Journal of Cardiology</i> , 2019, 293, 39-44.	1.6	67
215	Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 932-942.	7.5	41
216	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 827-843.	7.5	256

#	ARTICLE	IF	CITATIONS
217	Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , 2019, 12, e005998.	4.2	36
218	Acute heart failure congestion and perfusion status—Impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-AHA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1338-1352.	7.5	197
219	Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy. <i>ESC Heart Failure</i> , 2019, 6, 621-628.	3.1	20
220	The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-HF study. <i>European Journal of Heart Failure</i> , 2019, 21, 965-973.	7.5	195
221	Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0213198.	2.5	39
222	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019, 21, 665-675.	7.5	298
223	Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial. <i>ESC Heart Failure</i> , 2019, 6, 297-307.	3.1	7
224	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 321-332.	5.2	35
225	Seat belts-related behaviors in car drivers with cardiac implantable electronic devices. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 400-406.	1.2	2
226	Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2019, 21, 921-929.	7.5	94
227	Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 624-633.	7.5	71
228	Pulse pressure and prognosis in patients with heart failure with reduced ejection fraction. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13092.	3.4	1
229	The year in cardiology 2018: heart failure. <i>European Heart Journal</i> , 2019, 40, 651-661.	2.3	33
230	Heart rate and blood pressure monitoring in heart failure. <i>European Heart Journal Supplements</i> , 2019, 21, M13-M16.	0.1	11
231	Rationale and design of the AFFIRM-HF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1651-1658.	7.5	44
232	Drug therapy in elderly heart failure patients. <i>European Heart Journal Supplements</i> , 2019, 21, L8-L11.	0.1	6
233	Cognitive Decline Over Time in Patients With Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 1042-1053.	5.2	30
234	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50 62	7.5	70

#	ARTICLE	IF	CITATIONS
235	Monitoring of iron status in patients with heart failure. <i>European Heart Journal Supplements</i> , 2019, 21, M32-M35.	0.1	11
236	Assessment of baroreflex sensitivity has no prognostic value in contemporary, optimally managed patients with mild-to-moderate heart failure with reduced ejection fraction: a retrospective analysis of 5-year survival. <i>European Journal of Heart Failure</i> , 2019, 21, 50-58.	7.5	12
237	Multi-organ dysfunction/injury on admission identifies acute heart failure patients at high risk of poor outcome. <i>European Journal of Heart Failure</i> , 2019, 21, 744-750.	7.5	35
238	Iron Deficiency in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 36-46.	5.2	207
239	Patterns of dyspnoea onset in patients with acute heart failure: clinical and prognostic implications. <i>ESC Heart Failure</i> , 2019, 6, 16-26.	3.1	13
240	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2019, 108, 797-805.	3.5	10
241	Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2019, 21, 877-886.	7.5	72
242	Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. <i>ESC Heart Failure</i> , 2019, 6, 62-69.	3.1	46
243	Cardiovascular stress biomarker assessment of middle-aged non-athlete marathon runners. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 318-327.	1.8	21
244	Treatments targeting inotropy. <i>European Heart Journal</i> , 2019, 40, 3626-3644.	2.3	138
245	Structural and functional abnormalities in iron-depleted heart. <i>Heart Failure Reviews</i> , 2019, 24, 269-277.	3.9	37
246	Enzyme replacement therapy in Fabry disease in Poland – position statement. <i>Polish Archives of Internal Medicine</i> , 2019, 130, 91-97.	0.4	9
247	Comprehensive Heart Failure Care pilot study: starting point and expected developments. <i>Kardiologia Polska</i> , 2019, 77, 994-999.	0.6	8
248	Iron deficiency in heart failure: a 2020 update. <i>Kardiologia Polska</i> , 2019, 77, 1134-1139.	0.6	4
249	Clinical, respiratory, haemodynamic, and metabolic determinants of lactate in heart failure. <i>Kardiologia Polska</i> , 2019, 77, 47-52.	0.6	23
250	Elevated lactate in acute heart failure patients with intracellular iron deficiency as identifier of poor outcome. <i>Kardiologia Polska</i> , 2019, 77, 347-354.	0.6	19
251	Persistent hyperlactataemia is related to high rates of in-hospital adverse events and poor outcome in acute heart failure. <i>Kardiologia Polska</i> , 2019, 77, 355-362.	0.6	10
252	Relationship between the CHA2DS2-VASc score and atrial fibrillation in patients hospitalised due to heart failure. <i>Kardiologia Polska</i> , 2019, 77, 380-385.	0.6	2

#	ARTICLE	IF	CITATIONS
253	Phrenic nerve stimulation in patients with central sleep apnea: a single-center experience from pilot and pivotal trials evaluating the remedÅ“ System. <i>Kardiologia Polska</i> , 2019, 77, 553-560.	0.6	3
254	Recommendations on the use of innovative medical technologies in cardiology and cardiac surgery and solutions leading to increased availability for Polish patients. <i>Cardiology Journal</i> , 2019, 26, 114-129.	1.3	3
255	True worsening renal function identifies patients with acute heart failure with an ominous outcome. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 357-360.	0.4	7
256	Prognostic importance of serum troponin concentration in patients with an implanted cardioverter-defibrillator admitted to the emergency department due to electric shock. <i>Kardiologia Polska</i> , 2019, 77, 618-623.	0.6	2
257	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients who is doing what to whom and how?. <i>European Journal of Heart Failure</i> , 2018, 20, 1039-1051.	7.5	110
258	Acute heart failure: lessons learned, roads ahead. <i>European Journal of Heart Failure</i> , 2018, 20, 842-850.	7.5	17
259	Iron limitation promotes the atrophy of skeletal myocytes, whereas iron supplementation prevents this process in the hypoxic conditions. <i>International Journal of Molecular Medicine</i> , 2018, 41, 2678-2686.	4.1	12
260	Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. <i>American Journal of Cardiology</i> , 2018, 121, 1400-1408.	1.6	31
261	Depleted iron stores are associated with inspiratory muscle weakness independently of skeletal muscle mass in men with systolic chronic heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 547-556.	7.4	41
262	GuÃ“a ESC/EACTS 2017 sobre el tratamiento de las valvulopatÃ“as. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 110.e1-110.e47.	1.4	35
263	Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion. <i>European Journal of Heart Failure</i> , 2018, 20, 1011-1018.	7.5	99
264	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 386-398.	5.6	36
265	Proportional pulse pressure relates to cardiac index in stabilized acute heart failure patients. <i>Clinical and Experimental Hypertension</i> , 2018, 40, 637-643.	1.3	4
266	Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 260-267.	7.5	32
267	Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. <i>International Journal of Cardiology</i> , 2018, 253, 91-96.	1.6	2
268	Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2018, 20, 923-930.	7.5	57
269	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. <i>International Journal of Cardiology</i> , 2018, 253, 84-90.	1.6	55
270	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 180-188.	3.1	123



#	ARTICLE	IF	CITATIONS
271	Temporal trends in secondary prevention in myocardial infarction patients discharged with left ventricular systolic dysfunction in Poland. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 960-969.	1.8	20
272	Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. <i>International Journal of Cardiology</i> , 2018, 258, 185-191.	1.6	177
273	2018 ESC Guidelines for the diagnosis and management of syncope. <i>European Heart Journal</i> , 2018, 39, 1883-1948.	2.3	1,285
274	Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 125-133.	7.5	331
275	Iron deficiency and red cell indices in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 114-122.	7.5	55
276	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). <i>European Heart Journal</i> , 2018, 39, 763-816.	2.3	2,494
277	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2018, 39, 119-177.	2.3	7,452
278	Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 715-722.	7.5	49
279	Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 8-17.	5.2	143
280	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator. <i>JACC: Heart Failure</i> , 2018, 6, 96-104.	5.2	150
281	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRVO27: an exploratory subgroup analysis of BLAST-AHF. <i>Clinical Research in Cardiology</i> , 2018, 107, 170-181.	3.5	33
282	Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 3-15.	7.5	169
283	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. <i>Clinical Proteomics</i> , 2018, 15, 35.	2.2	7
284	Phrenic Nerve Stimulation for Central Sleep Apnea is Effective and Safe in the Presence of Concomitant Cardiac Devices. <i>Journal of Cardiac Failure</i> , 2018, 24, S17-S18.	1.7	1
285	Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1746-1754.	7.5	65
286	Effect of Implantable Cardioverter-Defibrillators by Etiology of Heart Failure: A Propensity-Matched Mortality Analysis of the WARCEF Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, S75.	1.7	0
287	Iron Depletion Affects Genes Encoding Mitochondrial Electron Transport Chain and Genes of Non-Oxidative Metabolism, Pyruvate Kinase and Lactate Dehydrogenase, in Primary Human Cardiac Myocytes Cultured upon Mechanical Stretch. <i>Cells</i> , 2018, 7, 175.	4.3	16
288	Iron deficiency as energetic insult to skeletal muscle in chronic diseases. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 802-815.	7.4	78

#	ARTICLE	IF	CITATIONS
289	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018, 271, 132-139.	1.6	151
290	Evaluation of Skeletal Muscle Function and Effects of Early Rehabilitation during Acute Heart Failure: Rationale and Study Design. <i>BioMed Research International</i> , 2018, 2018, 1-8.	2.0	11
291	Waist-to-hip ratio and mortality in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1269-1277.	7.5	90
292	Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta $\beta$ -adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta $\beta$ -left ventricular hypertrophy (Beta $\beta$ -LVH). <i>ESC Heart Failure</i> , 2018, 5, 830-841.	3.1	31
293	Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment. <i>ESC Heart Failure</i> , 2018, 5, 800-808.	3.1	26
294	Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion. <i>Circulation: Heart Failure</i> , 2018, 11, e004644.	4.2	60
295	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>European Heart Journal</i> , 2018, 39, 3165-3241.	2.3	1,538
296	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1081-1090.	5.6	216
297	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018, 39, 3867-3875.	2.3	49
298	Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). <i>American Journal of Cardiology</i> , 2018, 122, 821-827.	1.6	3
299	Validation of transurethral intra-abdominal pressure measurement in acute heart failure. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 403-405.	0.4	8
300	Coordinated heart failure care in Poland: towards optimal organisation of the health care system. <i>Kardiologia Polska</i> , 2018, 76, 479-487.	0.6	13
301	Impact of digoxin on risk of death in heart failure patients treated with b-blockers. Results from Polish part of ESC Heart Failure Long-Term Registry. <i>Kardiologia Polska</i> , 2018, 76, 1064-1072.	0.6	6
302	The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure. <i>Kardiologia Polska</i> , 2018, 76, 1336-1343.	0.6	15
303	Human carotid bodies as a therapeutic target: new insights from a clinician's perspective. <i>Kardiologia Polska</i> , 2018, 76, 1426-1433.	0.6	7
304	Clinical profile and management of outpatients with non-ischemic and non-hypertensive systolic heart failure: Analysis of the Polish DATA-HELP registry. <i>Cardiology Journal</i> , 2018, 25, 512-520.	1.3	2
305	Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 50.e1-50.e84.	1.4	14
306	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	4.2	12

#	ARTICLE	IF	CITATIONS
307	Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 760-767.	7.5	54
308	A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the <sc>RELAX-AHF</sc> trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1001-1010.	7.5	84
309	Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. <i>Clinical Research in Cardiology</i> , 2017, 106, 444-456.	3.5	9
310	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. <i>Heart</i> , 2017, 103, 407-413.	3.8	79
311	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 627-634.	7.5	191
312	Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 728-738.	7.5	35
313	Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 517-534.	3.2	4
314	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017, 376, 1956-1964.	30.1	263
315	Iron Deficiency Treatment in Patients with Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2017, 243, 561-576.	0.0	7
316	Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 243, 360-366.	1.6	44
317	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. <i>European Journal of Heart Failure</i> , 2017, 19, 800-809.	7.5	105
318	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the <sc>EDIFY</sc> randomized placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1495-1503.	7.5	161
319	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017, 38, 2364-2373.	2.3	110
320	Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the <sc>QUALIFY</sc> international registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1414-1423.	7.5	191
321	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 507-517.	5.2	86
322	Patient-reported outcomes in the <sc>SOLuble</sc> guanylate Cyclase <sc>stimuloR</sc> in <sc>heArT failurE patientS</sc> with <sc>PRESERVED</sc> ejection fraction (<sc>SOCRATES-PRESERVED</sc>) study. <i>European Journal of Heart Failure</i> , 2017, 19, 782-791.	7.5	86
323	Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 190, 113-122.	3.1	11
324	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimuloR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. <i>European Heart Journal</i> , 2017, 38, 1119-1127.	2.3	297

#	ARTICLE	IF	CITATIONS
325	Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 187, 62-69.	3.1	9
326	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , 2017, 19, 718-727.	7.5	17
327	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	30.1	522
328	Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 183-201.	2.3	36
329	Non-invasive approach for the assessment of sympathetic baroreflex function: A feasibility study. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2017, 203, 108-112.	2.7	1
330	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 616-664.	1.4	527
331	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2017, 19, 1361-1378.	7.5	121
332	Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1690-1697.	7.5	34
333	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2128-2136.	5.6	44
334	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2017, 38, 2739-2791.	2.3	5,257
335	What have we learned about heart failure with mid-range ejection fraction one year after its introduction?. <i>European Journal of Heart Failure</i> , 2017, 19, 1569-1573.	7.5	69
336	The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	7.5	143
337	Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients. <i>JACC: Heart Failure</i> , 2017, 5, 603-610.	5.2	3
338	Transvenous Phrenic Nerve Stimulation Effectiveness is Sustained at 18 Months: Data From the Remede System Pivotal Trial. <i>Chest</i> , 2017, 152, A734.	0.9	0
339	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1310-1320.	7.5	53
340	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation</i> , 2017, 136, 1374-1383.	9.3	311
341	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 281-293.	2.8	9
342	Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. <i>Clinical Research in Cardiology</i> , 2017, 106, 280-292.	3.5	17

#	ARTICLE	IF	CITATIONS
343	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Journal of Heart Failure</i> , 2017, 19, 9-42.	7.5	978
344	Carotid body resection for sympathetic modulation in systolic heart failure: results from firstâ€inâ€man study. <i>European Journal of Heart Failure</i> , 2017, 19, 391-400.	7.5	102
345	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 231-239.	1.7	34
346	Central Chemoreceptor Sensitivity Is Not Enhanced in Contemporary Patients With Chronic Systolic Heart Failure Receiving Optimal Treatment. <i>Journal of Cardiac Failure</i> , 2017, 23, 83-87.	1.7	3
347	Rationale for and design of the <sc>TRUEâ€AHF</sc> trial: the effects of ularitide on the shortâ€term clinical course and longâ€term mortality of patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 673-681.	7.5	32
348	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	48
349	Corrigendum to â€2017 ESC/EACTS Guidelines for the management of valvular heart diseaseâ€™ [Eur J Cardiothorac Surg 2017;52:616-664]â€. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 832-832.	1.4	14
350	The story of carotid body resection for HF. <i>European Heart Journal</i> , 2017, 38, 3481-3482.	2.3	3
351	Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1470.	4.2	17
352	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from <sc>BIOSTATâ€CHF</sc>. <i>European Journal of Heart Failure</i> , 2017, 19, 1284-1293.	7.5	80
353	Adherence to systolic heart failure guidelines in ambulatory care in Poland â€“ data from the international QUALIFY survey. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 657-665.	0.4	9
354	Both iron excess and iron depletion impair viability of rat H9C2 cardiomyocytes and L6G8C5 myocytes. <i>Kardiologia Polska</i> , 2017, 75, 267-275.	0.6	22
355	Acute heart failure in patients admitted to the emergency department with acute myocardial infarction. <i>Kardiologia Polska</i> , 2017, 75, 306-315.	0.6	4
356	Hospitalisation length and prognosis in heart failure patients. <i>Kardiologia Polska</i> , 2017, 75, 323-331.	0.6	10
357	InterAtrial Shunt Device (IASDÂ®) implantation â€” a novel treatment method for heart failure with preserved ejection fraction. <i>Kardiologia Polska</i> , 2017, 75, 736-741.	0.6	2
358	Attitude towards knowledge of the disease and psychological characteristics of patients with systolic heart failure. <i>Health Psychology Report</i> , 2017, 1, 30-40.	1.0	0
359	Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society. <i>Kardiologia Polska</i> , 2017, 75, 286-293.	0.6	0
360	Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society. <i>Kardiologia Polska</i> , 2017, 75, 33-41.	0.6	0

#	ARTICLE	IF	CITATIONS
361	Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure. <i>Stroke</i> , 2016, 47, 2031-2037.	5.3	48
362	Signature of circulating <scp>microRNAs</scp> in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 414-423.	7.5	168
363	Optimizing clinical use of biomarkers in high-risk acute heart failure patients. <i>European Journal of Heart Failure</i> , 2016, 18, 269-280.	7.5	75
364	The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications. <i>European Journal of Heart Failure</i> , 2016, 18, 762-773.	7.5	109
365	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from <scp>SHIFT</scp>. <i>European Journal of Heart Failure</i> , 2016, 18, 672-683.	7.5	21
366	Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. <i>European Journal of Heart Failure</i> , 2016, 18, 786-795.	7.5	287
367	Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the <scp>PROTECT</scp> study. <i>European Journal of Heart Failure</i> , 2016, 18, 830-839.	7.5	71
368	One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	4.2	119
369	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet</i> , 2016, 388, 2895-2903.	12.1	241
370	Iron Deficiency in Heart Failure. , 2016, , 535-547.		0
371	Contemporary Pharmacological Treatment of Heart Failure. , 2016, , 207-227.		0
372	Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes. <i>JACC: Heart Failure</i> , 2016, 4, 591-599.	5.2	50
373	The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2016, 219, 84-91.	1.6	9
374	Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia. <i>American Journal of Cardiology</i> , 2016, 117, 1482-1487.	1.6	13
375	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2016, 37, 2129-2200.	2.3	13,423
376	Increased body fat is associated with potentiation of blood pressure response to hypoxia in healthy men: relations with insulin and leptin. <i>Clinical Autonomic Research</i> , 2016, 26, 107-116.	2.5	12
377	Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure – Post-hoc analysis of the PROTECT trial. <i>International Journal of Cardiology</i> , 2016, 223, 967-975.	1.6	6
378	Guía ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. <i>Revista Española De Cardiología</i> , 2016, 69, 939.e1-939.e87.	1.4	21

#	ARTICLE	IF	CITATIONS
379	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	1.4	778
380	Impaired hepato-renal function defined by the MELD XI score as prognosticator in acute heart failure. European Journal of Heart Failure, 2016, 18, 1518-1521.	7.5	57
381	Could gonadal and adrenal androgen deficiencies contribute to the depressive symptoms in men with systolic heart failure?. Aging Male, 2016, 19, 221-230.	2.0	14
382	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. International Journal of Cardiology, 2016, 224, 231-239.	1.6	55
383	Acute heart failure in the young: Clinical characteristics and biomarker profiles. International Journal of Cardiology, 2016, 221, 1067-1072.	1.6	12
384	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. Circulation: Heart Failure, 2016, 9, .	4.2	97
385	Transvenous stimulation of the phrenic nerve for the treatment of central sleep apnoea: 12 months' experience with the remed <sup>Å</sup> System. European Journal of Heart Failure, 2016, 18, 1386-1393.	7.5	44
386	Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. European Journal of Heart Failure, 2016, 18, 641-649.	7.5	35
387	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	7.5	5,411
388	<scp>CHA<sub>2</sub>DS<sub>2</sub></scp>â€VASC</scp> score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. European Journal of Heart Failure, 2016, 18, 1261-1266.	7.5	27
389	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	2.3	5,796
390	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	1.6	3,645
391	Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. Lancet, The, 2016, 388, 974-982.	12.1	147
392	Iron deficiency in heart failure: Impact on response to cardiac resynchronization therapy. International Journal of Cardiology, 2016, 222, 133-134.	1.6	8
393	Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failureâ€€â€“ Subanalysis of the WARCEF Trial â€€. Circulation Journal, 2016, 80, 619-626.	1.6	11
394	2016 ESC and ACC/AHA/HFSA heart failure guideline update â€” what is new and why is it important?. Nature Reviews Cardiology, 2016, 13, 623-628.	13.8	39
395	Effects of selective carotid body stimulation with adenosine in conscious humans. Journal of Physiology, 2016, 594, 6225-6240.	2.9	29
396	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal, 2016, 37, 2105-2114.	2.3	293

#	ARTICLE	IF	CITATIONS
397	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	4.2	52
398	Influence of the availability of iron during hypoxia on the genes associated with apoptotic activity and local iron metabolism in rat H9C2 cardiomyocytes and L6G8C5 skeletal myocytes. <i>Molecular Medicine Reports</i> , 2016, 14, 3969-3977.	2.5	18
399	A systems <sc>BIOlogy</sc> Study to <sc>TAiored</sc> Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of <sc>BIOSSTATâ€CHF</sc>. <i>European Journal of Heart Failure</i> , 2016, 18, 716-726.	7.5	157
400	Patient journey after admission for acute heart failure: length of stay, 30â€day readmission and 90â€day mortality. <i>European Journal of Heart Failure</i> , 2016, 18, 1041-1050.	7.5	51
401	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	4.2	35
402	Physicians' adherence to guidelineâ€recommended medications in heart failure with reduced ejection fraction: data from the <sc>QUALIFY</sc> global survey. <i>European Journal of Heart Failure</i> , 2016, 18, 514-522.	7.5	202
403	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2016, 23, NP1-NP96.	1.8	707
404	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. <i>International Journal of Cardiology</i> , 2016, 204, 164-171.	1.6	35
405	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility inÂAcuteÂHeart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1444-1455.	5.6	201
406	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2016, 105, 727-737.	3.5	16
407	Could the two-minute step test be an alternative to the six-minute walk test for patients with systolic heart failure?. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1307-1313.	1.8	38
408	Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. <i>Lancet</i> , The, 2016, 387, 1178-1186.	12.1	386
409	GuÃa ESC/ERS 2015 sobre diagnÃstico y tratamiento de la hipertensiÃn pulmonar. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 177.e1-177.e62.	1.4	190
410	Relationship between central sleep apnea and CheyneâStokes Respiration. <i>International Journal of Cardiology</i> , 2016, 206, S8-S12.	1.6	12
411	The first prognostic model for stroke and death in patients with systolic heart failure. <i>Journal of Cardiology</i> , 2016, 68, 100-103.	1.9	14
412	The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure. <i>International Journal of Cardiology</i> , 2016, 205, 6-12.	1.6	109
413	Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 909-915.	1.6	69
414	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 564-569.	1.6	36



#	ARTICLE	IF	CITATIONS
415	A combined clinical and biomarker approach to predict diuretic response in acute heart failure. <i>Clinical Research in Cardiology</i> , 2016, 105, 145-153.	3.5	32
416	Nordic Walking May Safely Increase the Intensity of Exercise Training in Healthy Subjects and in Patients with Chronic Heart Failure. <i>Advances in Clinical and Experimental Medicine</i> , 2016, 25, 145-149.	1.6	5
417	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>Kardiologia Polska</i> , 2016, 74, 1037-1147.	0.6	208
418	Prediction of Post-Discharge Outcomes for Patients Hospitalized with Heart Failure: Results from PROTECT. <i>Journal of Cardiac Failure</i> , 2015, 21, S64.	1.7	0
419	Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. <i>European Journal of Heart Failure</i> , 2015, 17, 544-558.	7.5	324
420	Maintenance of serum potassium with sodium zirconium cyclosilicate (<sc>ZS</sc>â€š) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1050-1056.	7.5	152
421	Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015, 6, 325-334.	7.4	15
422	Central Sleep Apnea in Heart Failure Worsens Throughout the Night. <i>Chest</i> , 2015, 148, 1047A.	0.9	1
423	Growth differentiation factor 15 (<sc>GDF</sc>â€š15) in patients admitted for acute heart failure: results from the <sc>RELAXâ€šAHF</sc> study. <i>European Journal of Heart Failure</i> , 2015, 17, 1133-1143.	7.5	91
424	Sex differences in porcine left ventricular myocardial remodeling due to right ventricular pacing. <i>Biology of Sex Differences</i> , 2015, 6, 32.	4.2	5
425	Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the <sc>RELAXâ€šAHF</sc> study. <i>European Journal of Heart Failure</i> , 2015, 17, 1262-1270.	7.5	112
426	Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 697-706.	7.5	25
427	In-hospital worsening heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 1104-1113.	7.5	63
428	Anaemia (and iron deficiency?) in aortic stenosisâ€š a bystander or a potential therapeutic target?. <i>European Journal of Heart Failure</i> , 2015, 17, 994-996.	7.5	3
429	Clinical research Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) â€š Polish population. <i>Archives of Medical Science</i> , 2015, 4, 743-750.	0.9	8
430	Iohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure. <i>Croatian Medical Journal</i> , 2015, 56, 531-541.	0.9	5
431	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine â€š short version. <i>European Heart Journal</i> , 2015, 36, 1958-1966.	2.3	114
432	Psychological aspects of heart failure â€š beyond depression, anxiety and quality of life. <i>Health Psychology Report</i> , 2015, 3, 99-114.	1.0	5

#	ARTICLE	IF	CITATIONS
433	Design of the remed <sup>4</sup> System Pivotal Trial: A Prospective, Randomized Study in the Use of Respiratory Rhythm Management to Treat Central Sleep Apnea. <i>Journal of Cardiac Failure</i> , 2015, 21, 892-902.	1.7	46
434	Mechanisms and Clinical Consequences of <sup>5</sup> Untreated Central Sleep Apnea in Heart <sup>6</sup> Failure. <i>Journal of the American College of Cardiology</i> , 2015, 65, 72-84.	5.6	125
435	European Cardiac Resynchronization Therapy Survey II: rationale and design. <i>Europace</i> , 2015, 17, 137-141.	1.6	22
436	Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the <sc>PROTECT</sc> trial. <i>European Journal of Heart Failure</i> , 2015, 17, 109-118.	7.5	48
437	A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2015, 68, 846-851.	0.7	15
438	Heart Failure Therapeutics on the <sup>7</sup> Basis <sup>8</sup> of <sup>9</sup> A <sup>10</sup> Biased Ligand of the <sup>11</sup> Angiotensin-2 Type <sup>12</sup> 1 <sup>13</sup> Receptor. <i>JACC: Heart Failure</i> , 2015, 3, 193-201.	5.2	68
439	Evaluaci <sup>14</sup> 3n econ <sup>15</sup> 3mica de la utilizaci <sup>16</sup> 3n de hierro carboximaltosa en pacientes con deficiencia de hierro e insuficiencia cardiaca cr <sup>17</sup> 3nica en Espa <sup>18</sup> 3a. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 846-851.	1.4	19
440	Patogenia y presentaci <sup>19</sup> 3n cl <sup>20</sup> 3nica de la insuficiencia cardiaca aguda. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 331-337.	1.4	39
441	Late Cardiac Tamponade as a Result of Parietal Pericardium Erosion. <i>Annals of Thoracic Surgery</i> , 2015, 100, 715-717.	1.4	0
442	Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. <i>American Journal of Cardiology</i> , 2015, 116, 904-912.	1.6	7
443	Quality of Anticoagulation Control in Preventing Adverse Events in Patients With Heart Failure in Sinus Rhythm. <i>Circulation: Heart Failure</i> , 2015, 8, 504-509.	4.2	21
444	Iron deficiency and cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2015, 12, 659-669.	13.8	228
445	The impact of intravenous ferric carboxymaltose on renal function: an analysis of the <sc>FAIR <sup>21</sup> HF</sc> study. <i>European Journal of Heart Failure</i> , 2015, 17, 329-339.	7.5	95
446	Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study <sup>22</sup> Heart Failure (ARTS <sup>23</sup> HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015, 17, 224-232.	7.5	75
447	The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction. <i>European Heart Journal</i> , 2015, 36, 1974-1982.	2.3	198
448	Worsening Heart Failure Following Admission for Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 395-403.	5.2	46
449	Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. <i>European Heart Journal</i> , 2015, 36, 715-723.	2.3	72
450	Pathogenesis and Clinical Presentation of Acute Heart Failure. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2015, 68, 331-337.	0.7	16

#	ARTICLE	IF	CITATIONS
451	2015 ESC Guidelines for the diagnosis and management of pericardial diseases. <i>European Heart Journal</i> , 2015, 36, 2921-2964.	2.3	1,876
452	Exercise programs for LVAD supported patients: A snapshot from the ESC affiliated countries. <i>International Journal of Cardiology</i> , 2015, 201, 215-219.	1.6	32
453	Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea. <i>JACC: Heart Failure</i> , 2015, 3, 360-369.	5.2	114
454	CUPID 2: A Phase 2b Trial Investigating the Efficacy and Safety of the Intracoronary Administration of AAV1/SERCA2a in Patients with Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 939-940.	1.7	5
455	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2251.	7.0	304
456	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. <i>European Heart Journal</i> , 2015, 36, 657-668.	2.3	947
457	Bone marrow iron depletion is common in patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2015, 182, 517-522.	1.6	39
458	Vitamin B <sub>12</sub> and folate deficiency in chronic heart failure. <i>Heart</i> , 2015, 101, 302-310.	3.8	26
459	Abnormal serum calcium levels are associated with clinical response to maximization of heart failure therapy. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 54-64.	0.4	4
460	Cardioversion differences among first detected episode, paroxysmal, and persistent atrial fibrillation patients in the RHYTHM AF registry in Poland. <i>Cardiology Journal</i> , 2015, 22, 453-458.	1.3	4
461	Sexual dimorphism in socioeconomic differences regarding the risk factors, symptomatology and management of patients with stable coronary artery disease in Poland. <i>Cardiology Journal</i> , 2015, 22, 487-494.	1.3	3
462	Could an analysis of mean corpuscular volume help to improve risk stratification in non-anemic patients with acute myocardial infarction?. <i>Cardiology Journal</i> , 2015, 22, 421-427.	1.3	13
463	Atrial fibrillation in outpatients with stable coronary artery disease : results from the multicenter RECENT study. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 162-171.	0.4	10
464	Cognitive Function in Ambulatory Patients with Systolic Heart Failure: Insights from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. <i>PLoS ONE</i> , 2014, 9, e113447.	2.5	15
465	Skeletal myopathy in patients with chronic heart failure: significance of anabolic androgenic hormones. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014, 5, 287-296.	7.4	71
466	Predictors of Postdischarge Outcomes From Information Acquired Shortly After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 76-87.	4.2	112
467	Normal electrocardiographic and echocardiographic (M-mode and two-dimensional) values in Polish Landrace pigs. <i>Acta Veterinaria Scandinavica</i> , 2014, 56, 54.	1.6	36
468	Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. <i>European Heart Journal</i> , 2014, 35, 2468-2476.	2.3	193

#	ARTICLE	IF	CITATIONS
469	Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. <i>European Heart Journal</i> , 2014, 35, 1041-1050.	2.3	91
470	A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. <i>European Heart Journal</i> , 2014, 35, 431-441.	2.3	109
471	Rationale and design of the SOLuble guanylate Cyclase stimulator in heart Failure Studies (SOCRATES). <i>European Journal of Heart Failure</i> , 2014, 16, 1026-1038.	7.5	123
472	EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. <i>European Journal of Heart Failure</i> , 2014, 16, 583-591.	7.5	101
473	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 46, 517-592.	1.4	2,192
474	Heart failure: preventing disease and death worldwide. <i>ESC Heart Failure</i> , 2014, 1, 4-25.	3.1	1,044
475	Late-onset hypogonadism in men with systolic heart failure: prevalence, clinical associates, and impact on long-term survival. <i>ESC Heart Failure</i> , 2014, 1, 41-51.	3.1	5
476	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. <i>ESC Heart Failure</i> , 2014, 1, 52-58.	3.1	38
477	Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome – an analysis from RELAX-AHF. <i>European Journal of Heart Failure</i> , 2014, 16, 1230-1240.	7.5	137
478	Psychological Gender of Men With Systolic Heart Failure. <i>American Journal of Men's Health</i> , 2014, 8, 249-257.	1.6	5
479	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. <i>European Heart Journal</i> , 2014, 35, 1284-1293.	2.3	287
480	Dissociation between blood pressure and heart rate response to hypoxia after bilateral carotid body removal in men with systolic heart failure. <i>Experimental Physiology</i> , 2014, 99, 552-561.	2.0	52
481	Association of quality of life with anticoagulant control in patients with heart failure: The Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. <i>International Journal of Cardiology</i> , 2014, 177, 715-717.	1.6	4
482	Comparison of clinical profile and management of outpatients with heart failure with reduced left ventricular ejection fraction treated by general practitioners and cardiologists in contemporary Poland: The results from the DATA-HELP registry. <i>International Journal of Cardiology</i> , 2014, 176, 852-858.	1.6	8
483	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 2733-2779.	2.3	3,623
484	Consequences of peripheral chemoreflex inhibition with low-dose dopamine in humans. <i>Journal of Physiology</i> , 2014, 592, 1295-1308.	2.9	34
485	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 401-408.	4.2	36
486	Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 59-67.	4.2	60

#	ARTICLE	IF	CITATIONS
487	Design and Rationale of the Soluble Guanylate Cyclase Stimulator in Heart Failure Studies (SOCRATES). <i>Journal of Cardiac Failure</i> , 2014, 20, S39.	1.7	0
488	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	2.3	4,200
489	Considerable Regional Variation in AAV1 Neutralizing Antibodies and Its Consequences for a Multinational Clinical Trial of Gene Transfer for Advanced Heart Failure: The CUPID 2 Experience. <i>Journal of Cardiac Failure</i> , 2014, 20, S93.	1.7	0
490	Serum phosphorus level is related to degree of clinical response to up-titration of heart failure pharmacotherapy. <i>International Journal of Cardiology</i> , 2014, 177, 248-254.	1.6	6
491	Effect of Serelaxin on Mode of Death in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1591-1598.	5.6	56
492	Prevalence of Central Sleep Apnea in Patients Screened During the remedÅ® System Pilot Study. <i>Journal of Cardiac Failure</i> , 2014, 20, S117-S118.	1.7	0
493	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	2.3	2,642
494	Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. <i>International Journal of Cardiology</i> , 2014, 172, 588-594.	1.6	89
495	GuÃa de PrÃctica ClÃnica de la ESC 2013 sobre diagnÃstico y tratamiento de la cardiopatÃa isquÃmica estable. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 135.e1-135.e81.	1.4	14
496	Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study. <i>International Journal of Cardiology</i> , 2014, 174, 268-275.	1.6	154
497	Liver Function, In-Hospital, and Post-Discharge Clinical Outcome in Patients With Acute Heart Failure Results From the Relaxin for the Treatment of Patients With Acute Heart Failure Study. <i>Journal of Cardiac Failure</i> , 2014, 20, 407-413.	1.7	40
498	International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the <sc>PROTECT</sc> trial. <i>European Journal of Heart Failure</i> , 2014, 16, 614-624.	7.5	72
499	The additive burden of iron deficiency in the cardiorenal anaemia axis: scope of a problem and its consequences. <i>European Journal of Heart Failure</i> , 2014, 16, 655-662.	7.5	64
500	Improving care for patients with acute heart failure: before, during and after hospitalization. <i>ESC Heart Failure</i> , 2014, 1, 110-145.	3.1	235
501	Heart failure: preventing disease and death worldwide. <i>ESC Heart Failure</i> , 2014, 1, n/a-n/a.	3.1	8
502	Testosterone deficiency in men with heart failure: pathophysiology and its clinical, prognostic and therapeutic implications. <i>Kardiologia Polska</i> , 2014, 72, 403-409.	0.6	8
503	Demographic and clinical characteristics of patients with atrial fibrillation and cardioversion as planned therapeutic options in the International Registry on Cardioversion of Atrial Fibrillation RHYTHM-AF Polish substudy. <i>Kardiologia Polska</i> , 2014, 72, 700-706.	0.6	3
504	Does right ventricular pacing increase the risk of ventricular arrhythmias in patients with an implantable cardioverter-defibrillator?. <i>Kardiologia Polska</i> , 2014, 72, 381-384.	0.6	0

#	ARTICLE	IF	CITATIONS
505	Increase in heart failure mortality in Poland: can we explain the reasons?. Polish Archives of Internal Medicine, 2014, 124, 274-275.	0.4	0
506	Cardioversion of Atrial Fibrillation (RHYTHM-AF) International Registry in Poland. Cardiology Journal, 2014, 21, 484-491.	1.3	3
507	Distance covered during a six-minute walk test predicts long-term cardiovascular mortality and hospitalisation rates in men with systolic heart failure: an observational study. Journal of Physiotherapy, 2013, 59, 177-187.	3.2	42
508	Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis. International Journal of Cardiology, 2013, 168, 3878-3883.	1.6	30
509	Atrial Fibrillation Impairs the Diagnostic Performance of Cardiac Natriuretic Peptides in Dyspneic Patients. JACC: Heart Failure, 2013, 1, 192-199.	5.2	108
510	Iron deficiency in chronic heart failure: An international pooled analysis. American Heart Journal, 2013, 165, 575-582.e3.	3.1	560
511	Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. International Journal of Cardiology, 2013, 168, 789-794.	1.6	22
512	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Failure Reviews, 2013, 18, 107-122.	3.9	51
513	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. European Journal of Heart Failure, 2013, 15, 947-959.	7.5	75
514	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	2.3	1,791
515	Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. European Heart Journal, 2013, 34, 3128-3136.	2.3	58
516	Circulating testosterone and estradiol, autonomic balance and baroreflex sensitivity in middle-aged and elderly men with heart failure. Aging Male, 2013, 16, 58-66.	2.0	22
517	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. European Journal of Heart Failure, 2013, 15, 456-464.	7.5	39
518	Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2013, 15, 679-689.	7.5	30
519	Management of Chronic Heart Failure " Update 2013. Journal of Cardiac Failure, 2013, 19, S109.	1.7	0
520	Predicting heart failure outcome from cardiac and comorbid conditions: The 3C-HF score. International Journal of Cardiology, 2013, 163, 206-211.	1.6	112
521	Changes in parasympathetic system in medulla oblongata in male pigs in the course of tachycardia-induced cardiomyopathy. Autonomic Neuroscience: Basic and Clinical, 2013, 177, 253-259.	2.7	2
522	Actualizaci3n detallada de las gu3as de la ESC para el manejo de la fibrilaci3n auricular de 2012. Revista Espanola De Cardiologia, 2013, 66, 54.e1-54.e24.	1.4	14

#	ARTICLE	IF	CITATIONS
523	Carotid body removal for treatment of chronic systolic heart failure. <i>International Journal of Cardiology</i> , 2013, 168, 2506-2509.	1.6	84
524	The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1973-1981.	5.6	160
525	Clinical Predictors and Hemodynamic Consequences of Elevated Peripheral Chemosensitivity in Optimally Treated Men With Chronic Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 408-415.	1.7	44
526	Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. <i>Journal of the American College of Cardiology</i> , 2013, 61, 196-206.	5.6	404
527	Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. <i>Lancet</i> , The, 2013, 381, 29-39.	12.1	824
528	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2013, 34, 2159-2219.	2.3	5,742
529	Soluble guanylate cyclase: a potential therapeutic target for heart failure. <i>Heart Failure Reviews</i> , 2013, 18, 123-134.	3.9	123
530	Sex-specific acute heart failure phenotypes and outcomes from PROTECT. <i>European Journal of Heart Failure</i> , 2013, 15, 1374-1381.	7.5	53
531	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	2.3	3,973
532	Hypoglycaemia in diabetic patients: highly undesirable by cardiologists. <i>European Heart Journal</i> , 2013, 34, 3102-3105.	2.3	3
533	Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. <i>European Heart Journal</i> , 2013, 34, 2453-2463.	2.3	438
534	Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial. <i>Emergency Medicine Journal</i> , 2013, 30, 633-637.	2.0	12
535	Expression and Complex Formation of MMP9, MMP2, NGAL, and TIMP1 in Porcine Myocardium but Not in Skeletal Muscles in Male Pigs with Tachycardia-Induced Systolic Heart Failure. <i>BioMed Research International</i> , 2013, 2013, 1-12.	2.0	24
536	Value of serum pregnancy-associated plasma protein A for predicting cardiovascular events among patients presenting with cardiac chest pain. <i>Cmaj</i> , 2013, 185, E295-E303.	4.1	18
537	Iron status in patients with chronic heart failure. <i>European Heart Journal</i> , 2013, 34, 827-834.	2.3	226
538	Anabolic deficiencies in men with systolic heart failure: do co-morbidities and therapies really contribute significantly?. <i>Aging Male</i> , 2013, 16, 123-131.	2.0	8
539	Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. <i>European Heart Journal</i> , 2013, 34, 816-829.	2.3	317
540	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2013, 15, 1173-1184.	7.5	549

#	ARTICLE	IF	CITATIONS
541	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.	7.5	188
542	The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study. <i>European Journal of Heart Failure</i> , 2013, 15, 756-762.	7.5	28
543	Heart Failure in Patients With Atrial Fibrillation Is Associated With a High Symptom and Hospitalization Burden: The <sc>RealiseAF</sc> Survey. <i>Clinical Cardiology</i> , 2013, 36, 766-774.	1.9	23
544	Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1267-1276.	7.5	134
545	EUR <i>Observational</i> Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2013, 15, 808-817.	7.5	667
546	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2013, 34, 2281-2329.	2.3	2,209
547	Benefit of Warfarin Compared With Aspirin in Patients With Heart Failure in Sinus Rhythm. <i>Circulation: Heart Failure</i> , 2013, 6, 988-997.	4.2	38
548	The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. <i>European Heart Journal</i> , 2013, 34, 30-38.	2.3	141
549	Health locus of control and the sense of self-efficacy in patients with systolic heart failure: a pilot study. <i>Patient Preference and Adherence</i> , 2013, 7, 337.	1.9	20
550	Percutaneous reduction of mitral valve regurgitation using the MitraClip system – immediate and 90-day follow-up of 3 cases. <i>Postępy W Kardiologii Interwencyjnej</i> , 2013, 2, 126-131.	0.2	0
551	Sleep disordered breathing in patients with heart failure. <i>Cardiology Journal</i> , 2013, 20, 345-355.	1.3	13
552	Population of Polish patients participating in the Heart Failure Pilot Survey (ESC-HF Pilot). <i>Kardiologia Polska</i> , 2013, 71, 234-240.	0.6	12
553	Application of levosimendan in acute heart failure patients with symptoms of low cardiac output: case series report. <i>Kardiologia Polska</i> , 2013, 71, 275-278.	0.6	1
554	Andropausal syndrome in men with systolic heart failure. <i>Polish Archives of Internal Medicine</i> , 2013, 123, 156-169.	0.4	5
555	Iron deficiency in patients with chronic kidney disease requiring hemodialysis: do inflammation and overexpressed hepcidin contribute significantly?. <i>Polish Archives of Internal Medicine</i> , 2013, 123, 68-70.	0.4	0
556	Heart rate profile: from physiology to clinical practice. <i>Kardiologia Polska</i> , 2013, 71, 184-190.	0.6	0
557	Intracardiac thrombi in pulmonary embolism of a priori non high risk: therapeutic dilemma. <i>Kardiologia Polska</i> , 2013, 71, 399-402.	0.6	0
558	A 67-year-old men with not corrected tetralogy of Fallot. <i>Kardiologia Polska</i> , 2013, 71, 861-863.	0.6	0



#	ARTICLE	IF	CITATIONS
559	P-R interval in porcine model of chronic tachycardia-induced cardiomyopathy. Bulletin of the Veterinary Institute in Pulawy = Biuletyn Instytutu Weterynarii W Pulawach, 2013, 57, 437-441.	0.4	0
560	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	2.3	5,298
561	Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 632-639.	5.0	272
562	Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. European Journal of Heart Failure, 2012, 14, 882-886.	7.5	72
563	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. European Journal of Heart Failure, 2012, 14, 681-695.	7.5	71
564	Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. European Journal of Heart Failure, 2012, 14, 22-31.	7.5	48
565	Rationale and design of ARTS: a randomized, double-blind study of BAY 948862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure, 2012, 14, 668-675.	7.5	75
566	Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. European Journal of Heart Failure, 2012, 14, 782-790.	7.5	50
567	The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. European Journal of Heart Failure, 2012, 14, 605-612.	7.5	117
568	Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. European Journal of Heart Failure, 2012, 14, 278-286.	7.5	124
569	Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart, 2012, 98, 195-201.	3.8	112
570	Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failure. European Heart Journal, 2012, 33, 889-894.	2.3	118
571	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. Thrombosis and Haemostasis, 2012, 108, 1009-1022.	3.5	65
572	Anticoagulation for Heart Failure Patients in Sinus Rhythm: Common in Clinical Practice But Still Not Evidence-based. Revista Espanola De Cardiologia (English Ed ), 2012, 65, 687-689.	0.7	0
573	Anticoagulación para pacientes con insuficiencia cardiaca en ritmo sinusal: habitual en la práctica clínica, pero aún no basada en la evidencia. Revista Espanola De Cardiologia, 2012, 65, 687-689.	1.4	1
574	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Europace, 2012, 14, 1385-1413.	1.6	2,347
575	The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspnea. Biomarkers, 2012, 17, 490-497.	1.8	5
576	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	7.5	2,327

#	ARTICLE	IF	CITATIONS
577	Design of the RELAXin in Acute Heart Failure Study. <i>American Heart Journal</i> , 2012, 163, 149-155.e1.	3.1	60
578	Phrenic Nerve Stimulation Improves Circulatory Delay in Patients With Heart Failure and Central Sleep Apnea. <i>Journal of Cardiac Failure</i> , 2012, 18, S14-S15.	1.7	0
579	RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 85.	1.7	20
580	The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment. <i>Drug Safety</i> , 2012, 35, 233-244.	3.2	41
581	Ursodeoxycholic Acid in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 585-592.	5.6	77
582	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 938.e1-938.e59.	1.4	31
583	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 2719-2747.	2.3	3,172
584	CoreValve transcatheter aortic valve implantation complicated by stress cardiomyopathy (tako-tsubo) and septic shock. <i>Postepy W Kardiologii Interwencyjnej</i> , 2012, 4, 335-337.	0.2	0
585	Coronary rotational atherectomy in patients with unsuccessful classical angioplasty " in-hospital and six-month follow-up. <i>Postepy W Kardiologii Interwencyjnej</i> , 2012, 2, 85-90.	0.2	0
586	Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. <i>New England Journal of Medicine</i> , 2012, 366, 1859-1869.	30.1	521
587	Anemia in chronic heart failure: Can we treat? What to treat?. <i>Heart Failure Reviews</i> , 2012, 17, 203-210.	3.9	33
588	The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. <i>Clinical Research in Cardiology</i> , 2012, 101, 585-591.	3.5	38
589	Liver function tests in patients with acute heart failure. <i>Polish Archives of Internal Medicine</i> , 2012, 122, 471-479.	0.4	26
590	Costs of management of patients with coronary artery disease in Poland: the multicenter RECENT study. <i>Polish Archives of Internal Medicine</i> , 2012, 122, 599-607.	0.4	10
591	Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. <i>European Journal of Heart Failure</i> , 2011, 13, 961-967.	7.5	101
592	Effects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1899-1907.	5.6	125
593	Midregion Prohormone Adrenomedullin and Prognosis in Patients Presenting With Acute Dyspnea. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1057-1067.	5.6	130
594	Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, 899-906.	1.7	231

#	ARTICLE	IF	CITATIONS
595	Development of porcine model of chronic tachycardia-induced cardiomyopathy. <i>International Journal of Cardiology</i> , 2011, 153, 36-41.	1.6	19
596	Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. <i>Nature Reviews Cardiology</i> , 2011, 8, 485-493.	13.8	177
597	Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III Trial. <i>Cardiovascular Therapeutics</i> , 2011, 29, 89-98.	2.5	16
598	Japanese-Western Consensus Meeting on Biomarkers. <i>International Heart Journal</i> , 2011, 52, 253-265.	1.0	21
599	Single Night Transvenous Phrenic Nerve Stimulation Improves Central Sleep Apnoea In Systolic Heart Failure. , 2011, , .		0
600	Comparison of invasive and non-invasive measurements of haemodynamic parameters in patients with advanced heart failure. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 773-778.	1.5	40
601	Short-term Mortality Risk in Emergency Department Acute Heart Failure. <i>Academic Emergency Medicine</i> , 2011, 18, 947-958.	1.9	65
602	Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2011, 100, 745-753.	3.5	12
603	Changes in autonomic balance in patients with decompensated chronic heart failure. <i>Clinical Autonomic Research</i> , 2011, 21, 47-54.	2.5	27
604	Biomarkers in kidney and heart disease. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 62-74.	0.8	48
605	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2011, 13, 1-10.	7.5	355
606	'Iron deficiency: an ominous sign in patients with systolic chronic heart failure' [Eur Heart J 2010;31:1872-1880, doi:10.1093/eurheartj/ehq158]. <i>European Heart Journal</i> , 2011, 32, 1054-1054.	2.3	4
607	Anemia in Heart Failure: an Overview of Current Concepts. <i>Future Cardiology</i> , 2011, 7, 119-129.	1.1	16
608	Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin. <i>Circulation: Heart Failure</i> , 2011, 4, 613-620.	4.2	167
609	Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 724-732.	4.2	82
610	Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. <i>European Heart Journal</i> , 2011, 32, 1519-1534.	2.3	84
611	Identification of Chronic Heart Failure Patients with a High 12-Month Mortality Risk Using Biomarkers Including Plasma C-Terminal Pro-Endothelin-1. <i>PLoS ONE</i> , 2011, 6, e14506.	2.5	35
612	Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. <i>European Journal of Heart Failure</i> , 2010, 12, 499-507.	7.5	59

#	ARTICLE	IF	CITATIONS
613	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. <i>Circulation: Heart Failure</i> , 2010, 3, 314-325.	4.2	135
614	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Journal of Anaesthesiology</i> , 2010, 27, 92-137.	1.8	267
615	Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2010, 1, 187-194.	7.4	75
616	Treatment of Anemia With Darbepoetin Alfa in Heart Failure. <i>Congestive Heart Failure</i> , 2010, 16, 87-95.	1.9	6
617	Treating in-stent restenosis with drug-eluting balloon with intracoronary ultrasound control, with later optical coherent tomography control. <i>Postepy W Kardiologii Interwencyjnej</i> , 2010, 4, 203-207.	0.2	0
618	2010 Focused Update of ESC Guidelines on device therapy in heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 1143-1153.	7.5	152
619	Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2010, 12, 1130-1139.	7.5	90
620	Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 966-973.	7.5	32
621	Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. <i>European Journal of Heart Failure</i> , 2010, 12, 1238-1246.	7.5	15
622	Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1416-1420.	0.8	121
623	Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1777-1784.	0.8	32
624	Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1406-1416.	0.8	192
625	EUR-Observer Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2010, 12, 1076-1084.	7.5	349
626	Iron deficiency: an ominous sign in patients with systolic chronic heart failure. <i>European Heart Journal</i> , 2010, 31, 1872-1880.	2.3	538
627	Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 239-248.	7.5	215
628	EPO's rescue mission in acute myocardial infarction: still more hopes than evidence. <i>European Heart Journal</i> , 2010, 31, 2577-2579.	2.3	8
629	Mid-regional proadrenomedullin as a novel predictor of mortality in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 484-491.	7.5	118
630	Molecular Changes in Myocardium in the Course of Anemia or Iron Deficiency. <i>Heart Failure Clinics</i> , 2010, 6, 295-304.	2.4	42

#	ARTICLE	IF	CITATIONS
631	Nutritional Recommendations for the Management of Sarcopenia. Journal of the American Medical Directors Association, 2010, 11, 391-396.	2.6	563
632	Mid-Region Pro-Hormone Markers for Diagnosis and Prognosis in Acute Dyspnea. Journal of the American College of Cardiology, 2010, 55, 2062-2076.	5.6	472
633	Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal, 2010, 31, 2369-2429.	2.3	4,682
634	Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. International Journal of Cardiology, 2010, 143, 343-348.	1.6	40
635	Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function. Journal of Cardiac Failure, 2010, 16, 25-35.	1.7	76
636	The Effects of Adenosine A1 Receptor Antagonism in Patients With Acute Decompensated Heart Failure and Worsening Renal Function: The REACH UP Study. Journal of Cardiac Failure, 2010, 16, 714-719.	1.7	22
637	2010 Focused Update of ESC Guidelines on device therapy in heart failure. Europace, 2010, 12, 1526-1536.	1.6	298
638	Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. European Heart Journal, 2010, 31, 703-711.	2.3	820
639	Rolofylline, an Adenosine A <sub>1</sub> Receptor Antagonist, in Acute Heart Failure. New England Journal of Medicine, 2010, 363, 1419-1428.	30.1	479
640	2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. European Heart Journal, 2010, 31, 2677-2687.	2.3	429
641	Guidelines for the management of atrial fibrillation. Europace, 2010, 12, 1360-1420.	1.6	1,365
642	Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. European Heart Journal, 2009, 30, 1331-1339.	2.3	88
643	Circulating Estradiol and Mortality in Men With Systolic Chronic Heart Failure. JAMA - Journal of the American Medical Association, 2009, 301, 1892.	7.0	94
644	Home telemonitoring in heart failure patients: the HHH study (Home or Hospital in Heart Failure). European Journal of Heart Failure, 2009, 11, 312-318.	7.5	132
645	Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2009, 11, 433-443.	7.5	454
646	The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. European Journal of Heart Failure, 2009, 11, 1071-1077.	7.5	27
647	Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants. European Journal of Heart Failure, 2009, 11, 28-38.	7.5	54
648	Pathophysiological and clinical relevance of simplified monitoring of nocturnal breathing disorders in heart failure patients. European Journal of Heart Failure, 2009, 11, 264-272.	7.5	18

#	ARTICLE	IF	CITATIONS
649	Rationale and design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIRâ€CHF) study: a randomized, placeboâ€controlled study of intravenous iron supplementation in patients with and without anaemia. <i>European Journal of Heart Failure</i> , 2009, 11, 1084-1091.	7.5	106
650	Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. <i>European Heart Journal</i> , 2009, 30, 540-548.	2.3	289
651	European silver paper on the future of health promotion and preventive actions, basic research, and clinical aspects of age-related disease. <i>European Journal of Ageing</i> , 2009, 6, 51-57.	2.7	13
652	Reduction in Circulating Testosterone Relates to Exercise Capacity in Men With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2009, 15, 442-450.	1.7	87
653	Vasodilators in Acute Heart Failure (AHF): Does Blood Pressure Matter? Results from Pre-Relax-AHF. <i>Journal of Cardiac Failure</i> , 2009, 15, S74.	1.7	2
654	Changes in Dyspnea during Treatment of Acute Heart Failure Are Correlated with Clinical Signs, Rehospitalizations and Mortality. Results from the Pre-RELAX-AHF Trial. <i>Journal of Cardiac Failure</i> , 2009, 15, S62-S63.	1.7	3
655	Worsening Renal Function in Acute Heart Failure: Change in Blood Pressure and Effects of Relaxin. <i>Journal of Cardiac Failure</i> , 2009, 15, S63.	1.7	0
656	Time to Treatment and Vasodilator Efficacy in Acute Heart Failure: Results from the Pre-RELAX-AHF Study. <i>Journal of Cardiac Failure</i> , 2009, 15, S68.	1.7	1
657	Troponin Release in Patients Admitted with Acute Decompensated Heart Failure and Renal Dysfunction: Results from the Pilot Phase of the PROTECT Trial. <i>Journal of Cardiac Failure</i> , 2009, 15, S36-S37.	1.7	0
658	European Silver Paper. Documento europeo sobre el futuro de la promociÃ³n de la salud y las acciones preventivas, la investigaciÃ³n bÃ¡sica y los aspectos clÃnicos de las enfermedades relacionadas con el envejecimiento. <i>Revista Espanola De Geriatria Y Gerontologia</i> , 2009, 44, 61-65.	0.4	7
659	Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 219-228.	3.1	36
660	Sex Hormone-Binding Globulin and Heart Failure: a Passive Carrier of Steroid Hormones or an Active Hormone Itself?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 1353-1355.	0.7	5
661	GuÃa de prÃctica clÃnica para la valoraciÃ³n del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugÃa no cardiaca. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 1467.e1-1467.e56.	0.7	0
662	Silver paper: The future of health promotion and preventive actions, basic research, and clinical aspects of age-related disease. <i>Aging Clinical and Experimental Research</i> , 2009, 21, 376-385.	2.9	51
663	Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. <i>New England Journal of Medicine</i> , 2009, 361, 2436-2448.	30.1	1,699
664	Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. <i>Lancet, The</i> , 2009, 373, 1429-1439.	12.1	391
665	Globulina transportadora de hormonas sexuales: Â¿un transportador pasivo de hormonas esteroideas o una molÃcula hormonal activa en la insuficiencia cardiaca?. <i>Revista Espanola De Cardiologia</i> , 2009, 62, 1353-1355.	1.4	4
666	GuÃa de prÃctica clÃnica para la valoraciÃ³n del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugÃa no cardiaca. <i>Revista Espanola De Cardiologia</i> , 2009, 62, 1467.e1-1467.e56.	1.4	7

#	ARTICLE	IF	CITATIONS
667	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Heart Journal</i> , 2009, 30, 2769-2812.	2.3	741
668	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>European Heart Journal</i> , 2008, 29, 2388-2442.	2.3	2,677
669	Cachexia: A new definition. <i>Clinical Nutrition</i> , 2008, 27, 793-799.	5.1	1,970
670	ESC Guidelines for the Diagnosis And Treatment of Acute And Chronic Heart Failure 2008. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2008, 61, 1329.	0.7	12
671	Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency. <i>Journal of the American College of Cardiology</i> , 2008, 51, 103-112.	5.6	498
672	Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very poor outcome. <i>International Journal of Cardiology</i> , 2008, 129, 373-378.	1.6	13
673	The 12-week progressive quadriceps resistance training improves muscle strength, exercise capacity and quality of life in patients with stable chronic heart failure. <i>International Journal of Cardiology</i> , 2008, 130, 36-43.	1.6	64
674	Hematinics in Patients with Complicated Acute Myocardial Infarction: Results from an OPTIMAAL Substudy. <i>Journal of Cardiac Failure</i> , 2008, 14, S34.	1.7	0
675	Prognostic Value of Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure (CHF). <i>Journal of Cardiac Failure</i> , 2008, 14, S90.	1.7	0
676	Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. <i>Lancet, The</i> , 2008, 371, 228-236.	12.1	163
677	Corrigendum to "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008" [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. <i>European Heart Journal</i> , 2008, 29, 3069-3069.	2.3	47
678	Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. <i>European Journal of Heart Failure</i> , 2008, 10, 140-148.	7.5	139
679	Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. <i>European Heart Journal</i> , 2008, 30, 478-486.	2.3	254
680	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. <i>European Journal of Heart Failure</i> , 2008, 10, 933-989.	7.5	1,904
681	Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2007, 9, 684-694.	7.5	339
682	Response to Letter Regarding Article, "Anabolic Deficiency in Men With Chronic Heart Failure: Prevalence and Detrimental Impact on Survival". <i>Circulation</i> , 2007, 115, .	9.3	1
683	Excessive ventilation during early phase of exercise: A new predictor of poor long-term outcome in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 1024-1031.	7.5	16
684	Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. <i>European Heart Journal</i> , 2007, 28, 821-828.	2.3	87

#	ARTICLE	IF	CITATIONS
685	Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. <i>European Heart Journal</i> , 2007, 28, 2208-2216.	2.3	185
686	Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinez-Selles. <i>European Journal of Heart Failure</i> , 2007, 9, 1224-1225.	7.5	2
687	2007 Guidelines for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1105-1187.	0.5	4,825
688	A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. <i>Clinical Science</i> , 2007, 113, 205-212.	4.3	220
689	Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. <i>International Journal of Cardiology</i> , 2007, 115, 151-155.	1.6	65
690	Nuclear factor- $\kappa$ B activity in peripheral blood mononuclear cells in cachectic and non-cachectic patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2007, 122, 111-116.	1.6	14
691	Home telemonitoring of vital signs and cardiorespiratory signals in heart failure patients: System architecture and feasibility of the HHH model. <i>International Journal of Cardiology</i> , 2007, 120, 371-379.	1.6	25
692	Hyperhomocysteinemia in patients with symptomatic chronic heart failure: Prevalence and prognostic importance—pilot study. <i>Atherosclerosis</i> , 2007, 194, 408-414.	0.8	28
693	Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 753-762.	5.6	203
694	Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1054-1060.	5.6	410
695	Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1973-1980.	5.6	141
696	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2006, 28, 1462-1536.	2.3	1,629
697	EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. <i>European Heart Journal</i> , 2006, 27, 2725-2736.	2.3	1,092
698	Highlights of the 2006 Scientific Sessions of the European Society of Cardiology. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2564-2574.	5.6	3
699	Intravenous Iron Sucrose in Anemic and Non-anemic Iron Deficient Patients with CHF: A Randomized, Controlled, Observer-blinded Intervention Study (FERRIC-HF). <i>Journal of Cardiac Failure</i> , 2006, 12, S179.	1.7	1
700	Statin use and survival in patients with chronic heart failure—results from two observational studies with 5200 patients. <i>International Journal of Cardiology</i> , 2006, 112, 234-242.	1.6	91
701	Rationale and design of CIBIS III. <i>Country Review Ukraine</i> , 2006, 8, C35-C42.	0.9	0
702	Autonomic imbalance and immune activation in chronic heart failure—Pathophysiological links. <i>Cardiovascular Research</i> , 2006, 70, 434-445.	3.7	111



#	ARTICLE	IF	CITATIONS
703	Anabolic Deficiency in Men With Chronic Heart Failure. <i>Circulation</i> , 2006, 114, 1829-1837.	9.3	351
704	Reduced Peripheral Skeletal Muscle Mass and Abnormal Reflex Physiology in Chronic Heart Failure. <i>Circulation</i> , 2006, 114, 126-134.	9.3	138
705	Activation of the NF- $\kappa$ B system in peripheral blood leukocytes from patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2005, 7, 984-990.	7.5	20
706	Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence. <i>Circulation</i> , 2005, 112, 2426-2435.	9.3	308
707	Impaired Insulin Sensitivity as an Independent Risk Factor for Mortality in Patients With Stable Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1019-1026.	5.6	256
708	Beta-Blocker Treatment Before Angiotensin-Converting Enzyme Inhibitor Therapy in Newly Diagnosed Heart Failure. <i>Journal of the American College of Cardiology</i> , 2005, 46, 182.	5.6	1
709	Editorial comment on effect of exercise training in patients with heart failure. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2004, 11, 168-170.	2.8	0
710	Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III. <i>European Journal of Heart Failure</i> , 2004, 6, 493-500.	7.5	31
711	The association of lower testosterone level with coronary artery disease in postmenopausal women. <i>International Journal of Cardiology</i> , 2003, 87, 53-57.	1.6	32
712	Uric Acid and Survival in Chronic Heart Failure. <i>Circulation</i> , 2003, 107, 1991-1997.	9.3	543
713	Impact of periodic breathing on measurement of oxygen uptake and respiratory exchange ratio during cardiopulmonary exercise testing. <i>Clinical Science</i> , 2002, 103, 543-552.	4.3	19
714	Effect of altering conditions of the sequence method on baroreflex sensitivity. <i>Journal of Hypertension</i> , 2001, 19, 1279-1287.	0.5	39
715	Relation of heart rate and blood pressure turbulence following premature ventricular complexes to baroreflex sensitivity in chronic congestive heart failure. <i>American Journal of Cardiology</i> , 2001, 87, 737-742.	1.6	123
716	Very-low-frequency oscillations in heart rate and blood pressure in periodic breathing: role of the cardiovascular limb of the hypoxic chemoreflex. <i>Clinical Science</i> , 2000, 99, 125.	4.3	9
717	Very-low-frequency oscillations in heart rate and blood pressure in periodic breathing: role of the cardiovascular limb of the hypoxic chemoreflex. <i>Clinical Science</i> , 2000, 99, 125-132.	4.3	22
718	Contribution of skeletal muscle $\hat{a}$ ergoreceptors $\hat{a}$ ™ in the human leg to respiratory control in chronic heart failure. <i>Journal of Physiology</i> , 2000, 529, 863-870.	2.9	86
719	Echocardiographic determinants of mortality in patients >67 years of age with chronic heart failure. <i>American Journal of Cardiology</i> , 2000, 86, 158-161.	1.6	21
720	Cardiac autonomic dysfunction in AIDS is not secondary to heart failure. <i>International Journal of Cardiology</i> , 2000, 74, 133-137.	1.6	33

#	ARTICLE	IF	CITATIONS
721	Usefulness of the P Wave Signal-Averaged Electrocardiogram in Predicting Patients at Risk of Atrial Flutter and Fibrillation Induced by Transesophageal Pacing. <i>Annals of Noninvasive Electrocardiology</i> , 1999, 4, 46-52.	1.1	1
722	Effects of amiodarone on the P-wave triggered signal-averaged electrocardiogram in patients with paroxysmal atrial fibrillation and coronary artery disease. <i>American Journal of Cardiology</i> , 1999, 83, 112-114.	1.6	28
723	Impact of periodic breathing on and : a quantitative approach by Fourier analysis. <i>Respiration Physiology</i> , 1999, 118, 247-255.	2.9	8
724	A neural link to explain the "œmuscle hypothesis" of exercise intolerance in chronic heart failure. <i>American Heart Journal</i> , 1999, 137, 1050-1056.	3.1	128
725	Comparison between spectral analysis and the phenylephrine method for the assessment of baroreflex sensitivity in chronic heart failure. <i>Clinical Science</i> , 1999, 97, 503-513.	4.3	33
726	Comparison between spectral analysis and the phenylephrine method for the assessment of baroreflex sensitivity in chronic heart failure. <i>Clinical Science</i> , 1999, 97, 503.	4.3	18
727	Ventilatory response to exercise correlates with impaired heart rate variability in patients with chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1998, 82, 338-344.	1.6	60
728	Impaired baroreflex sensitivity and sympathovagal balance in syndrome X. <i>American Journal of Cardiology</i> , 1998, 82, 862-868.	1.6	39
729	Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure. <i>International Journal of Cardiology</i> , 1998, 66, 1-10.	1.6	55
730	Wasting as independent risk factor for mortality in chronic heart failure. <i>Lancet, The</i> , 1997, 349, 1050-1053.	12.1	1,230
731	Effects of Dihydrocodeine on Chemosensitivity and Exercise Tolerance in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 1997, 29, 147-152.	5.6	136
732	Clinical Correlates and Prognostic Significance of the Ventilatory Response to Exercise in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 1997, 29, 1585-1590.	5.6	509
733	Depressed Heart Rate Variability as an Independent Predictor of Death in Chronic Congestive Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy. <i>American Journal of Cardiology</i> , 1997, 79, 1645-1650.	1.6	438
734	Effect of Estrogen Replacement Therapy on Heart Rate Variability and Heart Rate in Healthy Postmenopausal Women. <i>American Journal of Cardiology</i> , 1997, 80, 815-817.	1.6	102
735	Hormonal Changes and Catabolic/Anabolic Imbalance in Chronic Heart Failure and Their Importance for Cardiac Cachexia. <i>Circulation</i> , 1997, 96, 526-534.	9.3	678
736	Augmented Peripheral Chemosensitivity as a Potential Input to Baroreflex Impairment and Autonomic Imbalance in Chronic Heart Failure. <i>Circulation</i> , 1997, 96, 2586-2594.	9.3	224
737	Heart rhythms, ventricular arrhythmias, and death in chronic heart failure. <i>Journal of Cardiac Failure</i> , 1996, 2, 177-183.	1.7	26
738	Reproducibility of Heart Rate Variability Indices during Exercise Stress Testing and Inotrope Infusion in Chronic Heart Failure Patients. <i>Clinical Science</i> , 1996, 91, 87-88.	0.0	16

#	ARTICLE	IF	CITATIONS
739	Reproducibility of Heart Rate Variability Measures in Patients with Chronic Heart Failure. <i>Clinical Science</i> , 1996, 91, 391-398.	4.3	31
740	Transient autonomic dysfunction precedes ST-segment depression in patients with syndrome X. <i>American Journal of Cardiology</i> , 1996, 77, 942-947.	1.6	28
741	Detection and significance of a discrete very low frequency rhythm in RR interval variability in chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1996, 77, 1320-1326.	1.6	62
742	Role of Catecholamines and Sympathetic Activation as a Risk Factor for Coronary Artery Disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1995, 2, 222-228.	2.8	7
743	P-wave signal-averaged electrocardiogram in patients with idiopathic mitral valve prolapse syndrome and supraventricular arrhythmias. <i>International Journal of Cardiology</i> , 1995, 50, 175-180.	1.6	10
744	Abnormal autonomic control of the cardiovascular system in syndrome X. <i>American Journal of Cardiology</i> , 1994, 73, 1174-1179.	1.6	95
745	The Role of Pharmacological Treatment in the Chemoreflex Modulation. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	6
746	Pathophysiology and Treatment Opportunities of Iron Deficiency in Heart Failure: Is There a Need for Further Trials?. <i>Current Heart Failure Reports</i> , 0, , .	3.2	0